When was Correvio founded?

Correvio was founded in 1986 and raised its 1st funding round 28 years after it was founded.

Where is Correvio located?

Correvio is headquartered in Vancouver, Canada.

How many employees does Correvio have?

As of Jul 01, 2024, the latest employee count at Correvio is 51 - 200.

Is Correvio a funded company?

Correvio is a funded company, having raised a total of $40M across 5 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Feb 21, 2014.

When was the latest funding round of Correvio?

Correvio's latest funding was a $***** Conventional Debt round on Mar 11, 2019, with participation from 0 investor.

Where does Correvio rank among its competitors?

Correvio ranks 194th amongst 1246 active competitors, of which 43 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Laboratorio Reig Jofre, which secured $14.7M in May, 2025.

Who are the top competitors of Correvio?

Correvio's top competitors include Bayer, Teva Pharmaceuticals and Wockhardt. Among them, Laboratorio Reig Jofre secured the most recent funding round in May, 2025.

Correvio - 2026 Company Profile, Funding & Competitors

Correvio is an acquired company based in Vancouver (Canada), founded in 1986. It operates as a Manufacturer of generic solid and liquid dosage forms. Correvio has raised $40M in funding. The company has 1246 active competitors, including 43 funded and 337 that have exited. Its top competitors include companies like Bayer, Teva Pharmaceuticals and Wockhardt.

Company Details

Correvio manufactures generic solid and liquid dosage forms such as tablets, capsules, liquid orals, and parenteral. The products are of various therapeutic categories including cardiovascular (BRINAVESS, AGGRASTAT), bacterial skin and skin structure infections, Pulmonary Arterial Hypertension, and others.

Website: correvio.com
Email ID: *****@correvio.com
Phone Number: +1 **********

Key Metrics

Founded Year

1986

Location

Vancouver, Canada

Stage

Acquired

Total Funding

$40M in 5 rounds

Latest Funding Round

Conventional Debt, Mar 11, 2019, $*****

Investors

CRG & 2 more

Ranked

194^th among 1246 active competitors

Employee Count

51 - 200 as on Jul 01, 2024

Similar Companies

Teva Pharmaceuticals & 1462 more

Exit Details

Acquired by Advanz Pharmaceutical (Mar 15, 2020)

View Correvio's full profile

Correvio got acquired by Advanz Pharmaceutical on Mar 15, 2020 at an acquisition amount of $*****.

Click here to take a look at Correvio's acquisition in detail

Correvio has raised a total funding of $40M over 5 rounds. Its first funding round was on Feb 21, 2014. Correvio has 3 institutional investors.

Here is the list of recent funding rounds of Correvio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 11, 2019	1894474	Conventional Debt	2847374	5208995	6993557	2152457
May 11, 2017	5376269	Conventional Debt	6217839	2748085	6350420	CRG
May 2017	6405927	Conventional Debt	3247131	5788876	6390584	3709851

Access funding benchmarks and valuations. Sign up today!

View details of Correvio's funding rounds and investors

Correvio's employee count trend

Correvio has 51 - 200 employees as of Jul 24. Here is Correvio's employee count trend over the years:

Uncover Correvio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Correvio include Bayer, Teva Pharmaceuticals and Wockhardt. Here is the list of Top 10 competitors of Correvio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bayer 1863, Leverkusen (Germany), Public	Manufacturer of drugs	-	Digital Pharma Lab, B Capital Fund & 9 others	76/100
2nd	Teva Pharmaceuticals 1901, Petah Tikva (Israel), Public	Traditional company engaged in manufacturing generics	$500M	Berkshire Hathaway, JANA Partners & 3 others	75/100
3rd	Wockhardt 1967, Mumbai (India), Public	Manufacturer of pharmaceuticals, biotechnology products, and active pharmaceutical ingredients	-	HDFC Mutual Fund, Tata Mutual Fund & 12 others	71/100
4th	Lupin 1968, Mumbai (India), Public	Manufacturer of pharmaceutical products, including generics, biosimilars, and active pharmaceutical ingredients	$6.64M	Cipher International, AbbVie & 5 others	71/100
5th	Biological E 1953, Hyderabad (India), Funding Raised	Developer of vaccines for treating multiple diseases	-	Gates, IFC & 3 others	69/100
6th	Cipla 1935, Mumbai (India), Public	Manufacturer of APIs, generic drugs, and formulation development services	-	MUFG, Eight Roads Ventures & 3 others	69/100
7th	The Alvogen 2009, Morristown (United States), Acquired	Developer and marketer of pharmaceutical products	$156M	Morgan Stanley, IMM Private Equity & 11 others	69/100
8th	Emcure 1981, Pune (India), Public	Developer, manufacturer, and markets a broad range of pharmaceutical products	$50M	Blackstone, Bain Capital	68/100
9th	Amneal 2002, Bridgewater (United States), Public	Manufacturer of generics formulations	-	Tarsadia, GE Capital & 2 others	68/100
10th	Laboratorio Reig Jofre 2000, Barcelona (Spain), Public	Manufacturer of pharmaceutical products and food supplements	-	CDTI, Europa	68/100
194th	Correvio 1986, Vancouver (Canada), Acquired	Manufacturer of generic solid and liquid dosage forms	$40M	CRG, PIPV Capital & 1 others	43/100